Atul Humar, MD, MSc Director, Transplant Program, University Health Network, University of Toronto

Transcription

1 TIME PROGRAM TITLE 7:30 8:15 Registration and Continental Breakfast 8:15 8:30 Welcoming Remarks TOPIC: VIRUSES Session Chair: Shahid Husain CMV: What is New, What s Hot Atul Humar, MD, MSc Director, Transplant Program, University Health Network, University of Toronto 8:30 9:00 CMV is one of the most common viral infections after transplantation. Prevention includes prophylaxis and pre-emptive strategies each with its pros and cons. New methods of prediction should help refine CMV prevention strategies and new antiviral drugs will help decrease the burden of CMV post-transplant. 1. Discuss current guidelines for CMV Prevention and Management 2. Discuss new developments in prediction, prevention and treatment of CMV 9:00 9:30 "Cold or Flu?": Implications of Respiratory Viruses in Transplant Recipients Deepali Kumar, MD MSc FRCPC FAST Professor, Faculty of Medicine, Transplant Infectious Diseases and Multi-organ Transplant Program, University Health Network / University of Toronto This presentation will provide a case-based overview of RVIs in organ transplant recipients. Up-to-date knowledge in the field and management strategies will be highlighted. 1. Review the epidemiology of RVI in transplantation 2. Identify the direct and indirect effects of respiratory viruses 3. List management pearls for RVIs BKV in Transplantation: What Now? 9:30 10:00 Greg Knoll, MD, MSc, FRCPC Head, Division of Nephrology

2 University of Ottawa Chair in Clinical Transplantation Research Professor, Department of Medicine, University of Ottawa Senior Scientist, Ottawa Hospital Research Institute The natural history of BK virus infection will be reviewed. Approaches to prevention and treatment will be discussed 1. Describe the natural history of BK virus infection in transplantation 2. Discuss approaches to the prevention and management of this condition 10:00 10:20 Morning Nutrition Break and Sponsor/Exhibit Viewing TOPIC: VIRUSES Session Chair: Deepali Kumar Do We Really have to Dread HCV in Hepatic and Non-Hepatic Transplantation? Jordan J. Feld, MD, MPH R. Phelan Chair, Translational Liver Research, Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network 10:20 10:50 Remarkable progress in HCV therapeutics allows us to cure almost all infected individuals, including those who have undergone liver or other organ transplantation. The data on treatment of HCV in the post-transplant context will be reviewed including new data on the use of HCV-infected organs for transplant to HCV uninfected individuals. 10:50 11:20 11:20 12:00 1. Appreciate the improvement in treatment of hepatitis C virus infection, with a particular focus on outcomes after transplantation 2. Recognize the opportunities for using HCV-infected organs for transplantation, including the risks, benefits and ethical considerations Transplantation in HIV: The New Realities Jose Camargo, MD Assistant Professor, Immunocompromised Host Section, Division of Infectious Diseases, University of Miami Miller School of Medicine This presentation will provide an overview of emerging concepts in the field of HIV and kidney transplantation. 1. Describe common challenges encountered by HIV+ kidney transplant candidates and recipients 2. Discuss the implications of pre-transplant CD4 count and protease inhibitorcontaining antiretroviral therapy regimens in transplant outcomes in HIV+ recipients 3. Understand the association between inflammation and immune activation with risk of rejection in HIV+ kidney transplant recipients Interesting Cases Faiqua Cheema, Mohammed Al Saeed, Seyed Hosseini 12:00 1:00 Lunch Break and Sponsor/Exhibit Viewing

3 TOPIC: FUNGAL Session Chair: Atul Humar Fungal Epidemiology and Evidence of Anti-Fungal Prophylaxis in Solid organ Transplant Recipients Shahid Husain, MD, MS, FECMM, FRCP(Edin) Professor, Faculty of Medicine, University of Toronto Director, Transplant Infectious Diseases Division of Infectious Diseases Multi-Organ Transplant program University Health Network 1:00 1:30 The presentation will provide the synopsis of the current epidemiology and risk factors of fungal infections in solid organ transplant recipients. It will also review the evidence for the use of antifungal prophylaxis and its rationale in different type of solid organ transplant recipients. 1. Understand the current epidemiology and risk factors of fungal infections in solid organ transplant recipients 2. Appreciate the current data on efficacy of antifungal prophylaxis strategies in different solid organ transplant recipients 3. Comprehend the current guidelines for antifungal prophylaxis is solid organ transplant recipients Use of Non-Cultural Based Methods for Anti-Fungal Management Me-Linh Luong, MD, FRCPC Assistant Professor, Department of Microbiology and Immunology, Faculty of Medicine, University of Montreal 1:30 2:00 This presentation will provide an overview of non-culture based diagnostic methods for fungal infection including: galactomannan, Aspergillus PCR, beta-d -glucan, and other fungal antigen detection tests. The performance and clinical utility in solid organ transplantation and bone marrow transplantation will be discussed. 1. Review the current diagnostic tests available for diagnosis of fungal infection 2. Understand clinical utility and limitations various fungal diagnostic test in management of immunocompromised patients Treatment Strategies for Invasive Candidiasis and Aspergillosis in Transplant Recipients 2:00 2:30 Coleman Rotstein, MD FRCPC,FACP, FECCM Professor, Division of Infectious Diseases, University of Toronto University Health Network Invasive candidiasis predominates as the most common invasive fungal infection in liver and kidney transplants while invasive aspergillosis is the most common in lung and heart transplant recipients. Effective strategies to treat these infections include prophylaxis, pre-emptive and early initiation of directed antifungal therapy.

4 2:30 3:10 1. Discuss the epidemiology of invasive candidiasis and aspergillosis in transplant recipients. 2. Describe the therapeutic strategies used in these patients. 3. Provide guidance for the optimum therapy for these infections. Interesting Cases Nancy Law, Herrera Sabina Herrera, Claire Aguilar 3:10 3:30 Afternoon Nutrition Break and Sponsor/Exhibit Viewing TOPIC: OTHER Session Chair: Coleman Rotstein MDR Bacteria in Transplantation: New Drugs, Resistance Mechanisms and Tests Robin Patel, MD(CM), D(ABMM), FIDSA, FACP, F(AAM) Elizabeth P. and Robert E. Allen Professor of Individualized Medicine, Professor of Microbiology and Medicine, Divisions of Clinical Microbiology and Infectious Diseases, Mayo Clinic, Rochester MN 3:30 4:00 This presentation will provide an overview of new antibacterial agents and resistance mechanisms in bacteria relevant to transplantation. Novel diagnostics for MDR bacteria will be presented. 1. List common MDR bacteria 2. Describe mechanisms of resistance in MDR bacteria 3. Discuss the application of novel diagnostics for MDR bacteria Vaccine in Transplantation Lara Danziger-Isakov, MD, MPH Professor, Department of Pediatrics, University of Cincinnati Director of Immunocompromised Host Infectious Disease, Cincinnati Children s Hospital Medical Center 4:00 4:30 This presentation will provide an overview of vaccination in Solid Organ Transplantation including assessment of vaccination status, pre-transplant vaccination, post-transplant vaccination and emerging vaccinations. 1. Detail the assessment of transplant candidates and recipients to assure vaccination optimization 2. Describe common issues related to vaccination in solid organ transplantation 3. Discuss the emerging vaccinations for solid organ transplant recipients. A Thorny Affliction: Mycobacterium Abscessus Lung Disease 4:30 5:00 Theodore Marras, MD, FRCPC (Respirology) Associate Professor, Department of Medicine, Division of Respirology, University of Toronto This presentation will provide an overview of Mycobacterium abscessus lung disease to include epidemiology and an illustration of the major short- and long-term challenges in managing this infection.

5 1. List factors that should be considered in deciding on management 2. List antimicrobial agents that may be useful and their most common toxicities 3. Discuss mechanisms and relevance of macrolide resistance 4. Propose an acceptable management plan 5:00 5:40 Midnight Calls for Transplant ID Physicians: Real Life Scenarios 5:45 6:45 Visionary Lecture: Transplant Infectious Diseases; Past, Present and Future Nina Singh, MD Professor, Faculty of Medicine, University of Pittsburgh Chief, Transplant Infectious Diseases, Pittsburgh VA Healthcare System 6:45 Closing Remarks